



## REVIEW

# Therapeutic implications of cancer stem cells in prostate cancer

Pinaki Banerjee<sup>1</sup>, Prachi Kapse<sup>2\*</sup>, Shehnaz Siddique<sup>3\*</sup>, Moumita Kundu<sup>3</sup>, Jasoda Choudhari<sup>4</sup>, Varshasnata Mohanty<sup>3</sup>, Diksha Malhotra<sup>3</sup>, Suresh W. Gosavi<sup>2</sup>, Rajesh N. Gacche<sup>4</sup>, Gopal C. Kundu<sup>3,5</sup>

<sup>1</sup>National Centre for Cell Science, Savitribai Phule Pune University Campus, Pune 411007, India; <sup>2</sup>School of Basic Medical Science, Savitribai Phule Pune University, Pune 411007, India; <sup>3</sup>School of Biotechnology, KIIT Deemed to be University, Bhubaneswar 751024, India; <sup>4</sup>Department of Biotechnology, Savitribai Phule Pune University, Pune 411007, India; <sup>5</sup>Kalinga Institute of Medical Sciences (KIMS), KIIT Deemed to be University, Bhubaneswar 751024, India

### ABSTRACT

Prostate cancer, one of the most frequently occurring cancers in men, is a heterogeneous disease involving multiple cell types within tumors. This tumor heterogeneity at least partly results from genomic instability leading to sub-clonal cellular differentiation. The differentiated cell populations originate from a small subset of cells with tumor-initiating and stem-like properties. These cells, termed prostate cancer stem cells (PCSCs), play crucial roles in disease progression, drug resistance, and relapse. This review discusses the origin, hierarchy, and plasticity of PCSCs; methods for isolation and enrichment of PCSCs; and various cellular and metabolic signaling pathways involved in PCSC induction and maintenance, as well as therapeutic targeting.

### KEYWORDS

Epithelial-mesenchymal transition; metastasis; prostate cancer; cancer stem cells; tumor growth; tumor microenvironment; signaling

## Introduction

Prostate cancer has the second-highest incidence rate and fifth-highest mortality rate among cancers affecting the world's male population<sup>1,2</sup>. Despite multiple advances in early detection and the availability of numerous prostate cancer treatments, limited progress has been made in treating locally advanced and metastatic forms of the disease. Most manifestations of prostate cancer initially respond to androgen deprivation therapy (ADT); however, many cases develop into an androgen-refractory form of the disease<sup>3</sup>. The heterogeneous population of cells within prostate tumors explains the many uncertainties involving the etiology and treatment of advanced disease.

Hanahan and Weinberg<sup>4</sup>, in 2000, described 6 hallmarks of cancer: insensitivity to anti-growth signals, evasion of apoptosis, limitless replicative potential, self-sufficiency in growth signals, sustained angiogenesis, and tissue invasion and metastasis. In 2011, they added another 4 emerging hallmarks: evasion of immune destruction, reprogramming of energy metabolism, tumor-promoting inflammation, and genomic instability and mutation<sup>5</sup>. However, with new knowledge and a better understanding of multiple aspects of tumorigenesis and disease progression, the hallmarks of cancer have been redefined as selective growth and proliferative advantage; altered stress responses favoring overall survival, vascularization, invasion, and metastasis; metabolic rewiring; a favorable microenvironment; and immune system modulation<sup>6</sup>. Prostate cancer stem cells (PCSCs), a cell population with self-renewal properties, eventually accumulate multiple heterogeneous mutations over time and consequently display several hallmarks of cancer, including resistance to various treatments<sup>7</sup>. The cancer stem cell (CSC) model of prostate cancer has gained attention in recent years because of its relevance to cancer prognostication and treatment<sup>8</sup>. In its basic form, the CSC model is hierarchical: CSCs reside at the top and possess the unlimited self-renewal ability, and progeny cells become increasingly differentiated and lose

\*These authors contributed equally to this work.

Correspondence to: Gopal C. Kundu

E-mail: gopalc.kundu@kiit.ac.in

ORCID ID: <https://orcid.org/0000-0003-3534-4033>

Received November 18, 2022; accepted April 12, 2023;

published online June 5, 2023.

Available at [www.cancerbiomed.org](http://www.cancerbiomed.org)

©2023 Cancer Biology & Medicine. Creative Commons

Attribution-NonCommercial 4.0 International License

their tumorigenic properties in the process<sup>9</sup>. In contrast, the stochastic concept of tumor heterogeneity proposes that all cells within a tumor have high tumorigenicity and bear various mutations and epigenetic modifications. These distinct concepts are not mutually exclusive and can coexist under an umbrella model involving multiple lineages of CSCs within a tumor, which undergo clonal evolution<sup>10</sup>.

The various signaling pathways that maintain homeostasis in healthy stem cells are often deregulated in cancer. The affected pathways associated with AKT, MAPK, Hedgehog, Notch, WNT, and Hippo, contribute to the formation and maintenance of CSCs in prostate cancer. Metabolic pathways and their reprogramming have been reported to participate in crosstalk with various molecular pathways and downstream transcription factors crucial for the induction and maintenance of CSCs. The metabolites, through multiple interactions, also modify the cellular niche, thus producing a CSC-favorable environment<sup>11</sup>. The Warburg effect allows cancer cells to utilize non-mitochondrial energy and essential by-product-producing pathways, through an aerobic glycolysis mechanism. The downregulation of oxidative phosphorylation (OXPHOS) pathways is associated with epithelial-to-mesenchymal transition (EMT) and promotes the conversion to a CSC phenotype<sup>12</sup>.

The therapeutic targeting of PCSCs in prostate cancer management is complex. These PCSCs usually lack androgen receptors (ARs) and thus do not respond to androgen hormone depletion therapy. Owing to inherent genetic instability, tumors can evolve new variants that become responsible for hormone-refractory disease<sup>7</sup>. The various signaling pathways involved in PCSC maintenance, in conjunction with the activity of ATP-binding cassette (ABC) transporters, have been implicated in conferring drug resistance on PCSCs. Cancer immunotherapy has achieved remarkable successes in recent years, and the cell surface markers that identify PCSCs have become targets for immunotherapies<sup>13</sup>. However, PCSCs acquire multiple mutations, thus enabling their evasion of immune surveillance and immunotherapy. Such mutations also confer adaptability and metastatic potential. Some commonly arising mutations include E26 transformation-specific (ETS) fusions, deletion of the NKX3-1 gene, and increased copy numbers of MYC and other genes<sup>14</sup>. This review focuses on understanding PCSCs by studying their origin, models, and various metabolic and signaling crosstalk associated with stem cell induction and maintenance and on describing recent therapeutic approaches to target these cells.

## PCSCs: origin, hierarchy, heterogeneity, and plasticity

Normal prostate tissue comprises 3 types of cells: luminal, basal, and neuroendocrine<sup>15</sup>. Mutations in these cell types can lead to uncontrolled cell division, which then develops into prostate cancer. According to literature reports, tumor initiators usually originate from the prostate epithelium's basal cell layer or luminal cells. Recent studies by Zhang et al.<sup>16</sup> have revealed the contribution of luminal progenitor cells to prostate cancer development and their role as drivers of tumor progression. A subset of cells known as CSCs exists within tumors and exhibit features of longevity, multipotency, and self-renewal<sup>17</sup>. CSCs also possess proliferative and regenerative capabilities and the potential for initiation of diversification and drug resistance<sup>18</sup>.


A distinct stem-cell-like population within prostate cancer has the tumor-initiating ability and conveys castration resistance<sup>19</sup>. Basal prostate stem cells express cell surface markers, including cytokeratin 5, cytokeratin 14, p63, integrin  $\alpha 2\beta 1$ , the cluster of differentiation 133 (CD133), and the cluster of differentiation 44 (CD44). They express less AR as compared to metastasized prostate cancer cells. This explains the CSC hierarchy<sup>20-22</sup>. Healthy prostate tissue stem cells have been postulated to arise from the basal compartment. In murine models, the basal population preferentially survives under androgen-depleted conditions, whereas most luminal-origin cells undergo apoptosis<sup>23,24</sup>. These normal prostate stem cells give rise to progenitor cells, and differentiated cells eventually arise through favoring of asymmetric cell division.

In contrast, both the basal and luminal cell populations can be cells of origin of PCSCs<sup>25</sup>. In human prostate cancer, basal cells have been reported to be the most likely origin<sup>26</sup>. Multiple crucial molecules such as p63, Bcl-2, and hTERT have been well documented to preferentially localize in the basal cell population of the prostate, thus giving rise to an alternative hypothesis in which PCSCs arise from normal prostate stem cells that have undergone malignant transformation. This possibility is supported by observations in basal cells in most metastatic prostate cancers<sup>27-29</sup>. However, luminal cells have also been postulated to be a potential origin of prostate cancer. Castration-resistant Nkx3.1-expressing cells, which are of luminal origin, have been demonstrated to be the cell of origin in some types of prostate cancer<sup>30</sup>. Researchers have

also reported that human prostate cancer is primarily luminal and have described the role of prostate luminal progenitor cells in tumorigenesis. However, the link between luminal cells and the PCSC cell of origin remains unclear because studies have been limited by challenges in stem cell-associated bioassays<sup>16</sup>. Another proposed origin of PCSCs is that they might arise from a fusion between normal prostate stem cells and other cancerous cells, including differentiated cells, stromal cells, or inflammatory cells. This hypothesis might explain why PCSCs have the self-renewal ability while also bearing the accumulated mutations present in differentiated cells, thus completing neoplastic transformation<sup>31</sup> (Figure 1A). De novo or ADT-dependent occurrence of neuroendocrine prostate cancer (NEPC) often generates more stem-like cells. In NEPC, genomic and epigenetic changes lead to the upregulation of stemness genes, such as SOX2 and c-Myc, and the downregulation of prostate-specific antigen (PSA) and AR expression.

Epigenetics is also crucial in promoting prostate cancer development and metastasis<sup>32</sup>. EZH2-mediated EMT leads to the enhancement of stemness properties and the progression of NEPC<sup>33</sup>.

The hierarchical stem cell model describes the unidirectional conversion of CSCs into progenitor cells, thereby giving rise to non-CSCs and multipotent cells. Dynamic CSC models can be characterized by the conversion of non-CSCs into CSCs and vice versa. In both hierarchical and dynamic models, CSCs have tumor-initiating potential (Figure 1B). Chromatin remodeling and histone modifiers control a dynamic equilibrium between CSCs and non-CSCs<sup>34</sup>. Castration-resistant prostate cancer (CRPC) has a phenotype of aldehyde dehydrogenase<sup>+</sup> (ALDH<sup>+</sup>), CD44<sup>+</sup>, and  $\alpha 2\beta 1^{+/hi}$ <sup>35</sup>. Patrawala et al.<sup>36</sup> have reported that CD44<sup>+</sup> enriched tumor cells develop xenografts more rapidly than CD44<sup>-</sup> cells, and  $\alpha 2\beta 1^{+/hi}$  cells show higher clonogenicity than  $\alpha 2\beta 1^{-/lo}$  cells *in vitro*. Analysis of



**Figure 1** PCSC origin, hierarchy, heterogeneity, and plasticity. (A) Schematic of the prostate gland, showing prostate cancer stem cells, progenitor cells, basal cells, luminal cells, and neuroendocrine cells. The fusion of differentiated, stromal, and inflammatory cells with normal prostate cells leads to the generation of cancer stem cells. Recent studies have indicated that luminal cells are the cells of origin. (B) Various hierarchical models, such as the dynamic CSC model, stochastic model, and hierarchical stem cell model, explain hypotheses regarding the origin of prostate cancer. (C) Heterogeneity among tumors results in the presence of diverse cell populations expressing various heterogeneity markers such as CD44,  $\alpha 2\beta 1$ , CD133, CD166, CD49f, ABCG2, NANOG, PSA, SOX2, and OCT4. (D) Plasticity explains the conversion of hormone-sensitive prostate cancer into castration-resistant prostate cancer, thus ultimately generating AR-negative prostate cancer.

patient samples has indicated that 70% of the cell population expresses both CD44 and  $\alpha 2\beta 1$  cell surface markers.

A tumor may have a single point of initiation due to mutations within normal stem cells, thus resulting in loss of control over the self-renewable phenotype<sup>37</sup>. CSCs and circulating tumor cells express stemness factors, such as TWIST, SLUG, and SNAIL, which promote aggressiveness and metastasis<sup>38</sup>. Prostate cancer sub-types of basal cell origin give rise to squamous carcinoma and adenocarcinoma. Myristoylated AKT1 (myr-AKT1) overexpression and N-MYC mutation result in the development of prostate adenocarcinoma, squamous carcinoma, and NEPC. Conditional deactivation of CK14-creER, P53, Smad4, and PTEN tumor suppressor genes in basal cells, along with ARR2PB-Cre and CK8-CreER in luminal cells, gives rise to the development of prostate adenocarcinoma. Inactivation of the RB1, PTEN, and P53 genes leads to NEPC growth. Mice bearing PTEN/RB1-deficient prostate adenocarcinoma, after undergoing castration or abiraterone treatment of PTEN/P53-deficient prostate adenocarcinoma, show generation of NEPC<sup>14</sup>. Non-treated prostate tumors express both AR and PSA. PSA, a biomarker used primarily for prostate cancer diagnosis, is a downstream target of AR<sup>39</sup>. After clonal evolution, with ADT, the expression of PSA decreases, and some cells undergo apoptosis, thus indicating tumor regression. High-grade prostate tumors exhibit low PSA expression, and AR therapy-resistant cells survive and develop castration-resistant cancer<sup>40</sup>. CRPCs developed after ADT have been found to express NK3 homeobox 1 (NKX3-1). These cells exhibit expression of other stem cell-like markers, such as CK18, and may serve as cells of origin<sup>30</sup>. Beyond PSA, CD44, CD49f, and CD49b can also be used as lineage-specific markers to identify the origin of PCSCs<sup>41</sup> (**Figure 1C**). Various paracrine growth factors, such as secreted frizzled-related protein 1 (SFRP1), stromal cell-derived factor 1 (SDF-1), and transforming growth factor- $\beta 1$  (TGF $\beta 1$ ), reside within the tumor-stroma microenvironment and promote the invasion of prostate cancer<sup>42-44</sup>. These factors have been found to activate anti-apoptotic pathways and promote invasion. PCSC phenotypes are also regulated by downstream targeting of the NF $\kappa$ B and JAK-STAT pathways by these factors<sup>45</sup>.

Stable integration of the hTERT vector into the human prostate epithelial (HPE) cell line led to the establishment of the HPET cell line (where T indicates hTERT). A study using HPE cell lines has provided an understanding of the development of prostate cancer after AR deprivation. The HPET cell line unexpectedly has been found to express stemness factors,

such as SOX2, NANOG, OCT4, Nestin, CD44, and CD133, but not p63 and AR. HPET retains the expression of all 3 types of epithelial cells and develops into prostate tumors<sup>25</sup>. Although the mechanism driving lineage plasticity in prostate cancer remains unclear, plasticity within the epithelial cell population of a mixed basal-luminal phenotype depends on JAK-STAT and FGFR signaling. Single-cell analysis has confirmed that JAK/STAT and FGFR signaling determines lineage plasticity in prostate cancer. Keratin 13 (KRT 13) is enriched in prostate stem cells at single-cell resolution, according to prostasphere-based label retention assays. Single-cell RNA-seq analysis has revealed 3 clusters of PCSCs: cluster I (PSCA, CD36, SPINK1, and KRT13/23/80/78/4 enriched) representing quiescent stem cells; cluster II representing active stem cells; and cluster III (KRT16/17/6 enriched) representing bipotent progenitor cells<sup>44</sup>.

Luminal progenitors serve primarily as tumor initiators or cells of origin for prostate cancer. Various hierarchical models have been proposed. A recent model suggests that, during early postnatal development, multipotent basal cells (p63<sup>+</sup> CK5<sup>+</sup>) differentiate into unipotent basal progenitors, luminal progenitors (CK8<sup>+</sup> AR low), and NE cells. These unipotent basal and luminal progenitors can undergo self-renewal or differentiate into basal cells and mature luminal cells (AR<sup>+</sup> CK8<sup>+</sup>), respectively. In adults, during homeostasis and regeneration, the bipotent basal progenitor forms unipotent basal and luminal progenitors, which further undergo self-renewal. Unipotent basal progenitors differentiate into basal cells, and luminal cell progenitors differentiate into luminal cells.

In contrast, different groups have reported that bipotent basal progenitors might also give rise to basal and luminal cells. Tumor heterogeneity at various levels—such as the epigenetic, post-translational, morphological, and phenotypic levels—can be examined to assess clonal and subclonal changes<sup>45</sup>. Heterogeneity at the genetic level poses diagnostic challenges, and sequencing studies have indicated that individual tumor foci can give rise to clonally distinct lesions without sharing driver gene alterations. Acquired drug resistance in prostate cancer changes the cell phenotype, and AR-independent pathways are adopted for growth and survival (**Figure 1D**). The aggressive prostate tumor results in epithelial to mesenchymal plasticity during reactivation of the developmental program. We have established an understanding of the link between NEPC emergence and plasticity. Enhanced knowledge of prostate cancer is expected to lead to improvements in treatment and clinical management<sup>46</sup>.

## Current methods for PCSC enrichment and analysis

PCSCs express specific markers that can be used to isolate and enrich these cell populations. Enrichment can be achieved by sorting cells from prostate cancer cell lines and patient tissues by identifying specific surface markers. Prostate stem/progenitor cells have been reported to express various cell surface markers such as CD44, integrin  $\alpha 2\beta 1$ , CD133, CD166, and ATP-binding cassette sub-family G member 2 (ABCG2)<sup>47</sup> (Table 1, Figure 2). Cells expressing CD44<sup>+</sup> along with  $\alpha 2\beta 1^{+/hi}$  are as tumorigenic as CD44<sup>+</sup> and  $\alpha 2\beta 1^{-/lo}$  cells. CD44<sup>-</sup> and  $\alpha 2\beta 1^{+/hi}$  cells exhibit more tumorigenic potential than CD44<sup>-</sup> and  $\alpha 2\beta 1^{-/lo}$  cells. CD44 is a prominent stemness marker, whereas  $\alpha 2\beta 1$  is more aligned with the hierarchical depiction of the PCSCs and their metastatic characteristics<sup>36</sup>. “Side populations” obtained through Hoechst dye exclusion assay represent stem cell phenotypes. Isolation and enrichment of CSCs can be performed with Hoechst 33342 and Rhodamine 123<sup>48</sup>. Strategically repeated chemotherapy and radiotherapy increase the numbers of cancer cell-rich in CSC markers, mainly because of acquired treatment resistance. Enriched chemotherapy-resistant carcinoma cells are tumorigenic, metastatic, and highly aggressive. A particular treatment-resistant CSC population is enriched in the ABC transporter protein ABCG2. Tumor cells from cell lines and patient-derived xenografts can be analyzed for ABCG2 enrichment through flow cytometry sorting of cancer cells with high efflux of dyes such as Hoechst 33342 and Rhodamine 123<sup>42,43</sup>. Studies have suggested that CSCs may be identified by selecting a marker-based population or de-differentiation of cells.

CSCs within the side population are highly aggressive and possess tumor initiation and self-renewal abilities, and hence can develop into heterogeneous tumors. Fluorescence-activated cell sorting (FACS) or magnetic cell sorting (MACS) techniques can be used to sort CSCs by using antibodies tagged with different fluorophores or magnetic beads for phenotypic separation, respectively<sup>49,50</sup>. The absence of specific cell surface markers, such as CD24, may also be used to sort CSCs across different cell lines, xenograft tumors, and patient-derived specimens<sup>51</sup>. Hence, marker-based studies of CSC populations are often reliable and specific. A detailed understanding of CSC characteristics is needed to improve the efficacy and accuracy of CSC-based studies.

Although stem cells may be characterized according to cell surface markers, they can also be sorted by reporter gene assays using the promoters of intracellular PCSC markers such as NANOG, PSA, SOX2, and OCT4<sup>52-55</sup>. PSA high or PSA low cells, or cells with no PSA, vary in their biological functionality. Clinical studies have revealed that prostate cancer cells with low PSA expression are resistant to various drugs and anti-androgen therapy. Evidence has suggested that a PSA low population mimics the characteristic features of PCSCs<sup>55</sup>.

Li et al.<sup>56</sup> have reported that CSCs can be more invasive than cancer cells. Sphere formation is a cell adhesion-independent process. Cells forming spheres for multiple passages are self-renewing and highly proliferative, showing spherogenicity for numerous generations. Sphere-forming cells have been found to have intracellular and cell surface CSC-marker expression<sup>57</sup>.

## Signaling networks involved in CSC maintenance

The molecular pathways involved in maintaining normal stem cell homeostasis are often deregulated in CSCs. Such abnormal signaling is involved in self-renewal, differentiation, proliferation, and drug resistance in CSCs. These pathways crosstalk with other signaling pathways involved in various extrinsic and intrinsic processes<sup>58</sup>. Several signaling cascades, such as Notch, WNT, Hedgehog, Hippo, PI3K/AKT, RAS/MAPK, and STAT3, have been reported to maintain PCSCs<sup>59</sup> (Figure 3).


### PI3K/AKT signaling

PI3K, a frequently dysregulated signaling pathway in most cancers, increases EMT properties, drug resistance, and stemness. PI3K stimulates the mammalian target of rapamycin (mTOR) through the activation of AKT. PTEN, which negatively regulates PI3K/AKT signaling, is often mutated or deleted in multiple cancers<sup>3</sup>. Loss of PTEN and overexpression of PI3K/AKT induce stem-like properties and sphere formation in prostate cancer cells, such as LNCaP, DU145, and PC3. Elevated AKT activity has been observed in clinical specimens with a Gleason grading of 8 and higher<sup>59</sup>. PTEN knockdown in prostate cancer cell lines increases sphere-forming properties and enrichment in CD44<sup>+</sup>/CD133<sup>+</sup> cells<sup>60</sup>. Increased PI3K/AKT signaling pathway activity is also associated with resistance to radiotherapy by enhancing CSC and EMT phenotypes<sup>61</sup>. AKT1/2 has



**Table 1** Various markers for prostate cancer stem cells and methods of enrichment/analysis

Stemness marker	Method of enrichment/analysis	Effect	Stemness marker in other cancer	Ref.
<b>CD44</b>	FACS, MACS, sphere formation assay, immunofluorescence microscopy, IHC	Tumor progression	Colorectal cancer, lung cancer, breast cancer, leukemia, pancreatic cancer, head and neck cancer	180
		Self-renewal ability		181
		Expression of stemness genes		182
		Metastasis		19
<b>CD133</b>	FACS, MACS, sphere formation assay, immunofluorescence microscopy, IHC	Tumor progression	Brain cancer, colorectal cancer, lung cancer, ovarian cancer, liver cancer	180
		Self-renewal ability		181
		Expression of stemness genes		182
<b>CD117/c-kit</b>	FACS, MACS, sphere formation assay, immunofluorescence microscopy, IHC	Tumor progression	Gastrointestinal stromal cancer, melanoma, small cell lung carcinoma, leukemia	183
		Metastasis		184
		Recurrence and therapeutic resistance		183
<b><math>\alpha_2\beta_1</math> integrin</b>	FACS, MACS, sphere formation assay, immunofluorescence microscopy, IHC	Tumor progression	Colorectal cancer, non-small cell lung cancer	185
		Self-renewal ability		186
		Recurrence and therapeutic resistance		185
<b><math>\alpha_6</math> integrin</b>	FACS, MACS, sphere formation assay, immunofluorescence microscopy, IHC	Tumor progression	Glioblastoma	185
		Self-renewal ability		181
		Recurrence and therapeutic resistance		185
<b>CXCR4</b>	FACS, sphere formation assay, immunofluorescence microscopy, IHC	Tumor progression	Leukemia, brain cancer, breast cancer, retinoblastoma, ovarian cancer, cervical cancer	187
		Self-renewal ability		188
		Recurrence and therapeutic resistance		189
		Metastasis		
<b>CD166</b>	FACS, MACS, sphere formation assay, immunofluorescence microscopy, IHC	Tumor progression	Bladder cancer, breast cancer, colorectal cancer, lung cancer, head and neck cancer, ovarian cancer, melanoma	190
		Self-renewal ability		190
		Recurrence and therapeutic resistance		190
<b>ABCG2</b>	Immunoblotting, qPCR	Recurrence and therapeutic resistance	Pancreatic cancer, melanoma, glioma	191
<b>ALDH1</b>	FACS	Tumor progression	Liver cancer, lung cancer, breast cancer, colorectal cancer, pancreatic cancer, ovarian cancer	192
		Self-renewal ability		192
		Recurrence and therapeutic resistance		193
		Expression of stemness genes		193
<b>EZH2</b>	Immunoblotting, qPCR	Tumor progression	Breast cancer, pancreatic cancer, ovarian cancer, melanoma, colorectal cancer, leukemia, hepatocarcinoma	194
		Metastasis		195
		Recurrence and therapeutic resistance		196
		Expression of stemness genes		194
<b>Trop2</b>	FACS, MACS, sphere formation assay, immunofluorescence microscopy, IHC	Tumor progression	Pancreatic cancer, ovarian cancer, lung cancer, breast cancer, colorectal cancer	197
		Self-renewal ability		198
<b>PSA</b>	Gene reporter system-based FACS, immunofluorescence microscopy	Tumor progression	-	35
		Self-renewal ability		35
		Recurrence and therapeutic resistance		35
		Expression of stemness genes		199



**Figure 2** Enrichment of PCSCs. (A) Sphere formation assays: CSCs can form spheres. (B) Size-based cell sorting, based on the smaller size of CSCs than cancer cells. (C) Fluorescence-associated cell sorting (FACS), used for sorting PCSCs by using fluorescently labeled antibodies. (D) Magnetic-activated cell sorting (MACS), in which antibodies that bind PCSC markers are labeled with magnetic beads.

been reported to be involved primarily in regulating chemoresistance in prostate cancer<sup>62</sup>.


### RAS/MAPK signaling

MAPKs are evolutionarily conserved cytoplasmic serine/threonine kinases. The MAPK signaling pathway responds to extracellular stimuli, thereby regulating fundamental cellular processes such as cell growth, proliferation, migration, differentiation, and apoptosis<sup>63</sup>. MAPK signaling is responsible for stem cell characteristics in prostate cancer cells. DU145 cells exhibit a decrease in sphere-forming ability after treatment with the MEK inhibitor U0126 or knockdown of ERK<sup>64</sup>. RAS activation, PI3K/AKT activation, and loss of PTEN induce an increase in the EMT phenotype and macro-metastasis in prostate cancer<sup>65</sup>. Aberrant fibroblast growth factor receptor (FGFR) signaling has been reported to induce EMT and

stemness in prostate cancer cell lines by activating the RAS/MAPK, PI3K/AKT, and JAK/STAT pathways. High expression of p-AKT, p-STAT5, and p-MAPK has also been reported in spheroids generated from PC3, DU145, and LNCaP cells<sup>66</sup>.

### Signal transducer and activator of transcription 3 (STAT3) signaling

Upregulated STAT signaling has been well documented in prostate cancer, and elevated STAT3 activation has been observed in prostate cancers and adjacent normal prostate tissues<sup>67</sup>. However, STAT3 signaling has been recently reported to be responsible for the CSC phenotype in prostate cancer cells. Loss of AR results in IL6-mediated STAT3 activation. Activated STAT3 induces the development of PCSCs<sup>68</sup>.  $\alpha 2\beta 1^{\text{hi}}/\text{CD133}^+$  cells isolated from human prostate cancer patient samples also show elevated expression of IL6 and STAT3<sup>69</sup>.



**Figure 3** Various signaling pathways, such as JAK/STAT, WNT/ $\beta$ -catenin, Hippo, Notch, Hedgehog, PI3K/AKT, and Ras/Raf/MEK/ERK, both individually and through crosstalk, regulate the transcription of OCT3/4, SOX2, NANOG, KLF4, and cMyc, thus maintaining the stemness of the prostate cancer stem cells.

## Notch signaling

Notch signaling regulates differentiation in the benign prostate and determines the structure of the prostate gland. However, in prostate cancer, activated Notch signaling increases the survival of cancer cells. The expression of Notch pathway-associated proteins such as Jagged2, Notch3, and Hes6 is enhanced in higher grades of cancer<sup>70</sup>. Deregulated Notch signaling in prostate cancer is responsible for tumor recurrence, resistance to treatment, EMT phenotype, and stem-like properties<sup>71</sup>.

## Hedgehog signaling

Aberrant Hedgehog signaling has been associated with the development of different types of cancers and implicated in many aspects of tumorigenesis, including CSC maintenance<sup>72</sup>.

During prostate development, autocrine and paracrine Hedgehog signaling regulates growth and differentiation. Hedgehog signaling is responsible for the enrichment of stemness through autocrine and paracrine mechanisms in prostate cancer<sup>73</sup>. Hedgehog activity increases with higher prostate cancer grades and is responsible for EMT and subsequent metastasis<sup>74</sup>. Aberrant Hedgehog signaling induces drug resistance in CD133<sup>high</sup>/CD44<sup>high</sup> PCSCs<sup>75</sup>.

## WNT signaling

Dysregulation or mutation of various genes associated with the WNT pathway has also been associated with cancer development and progression<sup>76</sup>. The WNT pathway has been extensively associated with the self-renewal ability of prostate cancer cells and other stem-like characteristics. Inhibition of the WNT



pathway decreases both sphere size and self-renewal ability in prostate cancer cell lines. Alternatively, an increase in WNT3a has been associated with the increased sphere-forming ability of prostate cancer cells<sup>77</sup>. WNT/ $\beta$ -Catenin signaling induces self-renewal and symmetric cell division in hTERT<sup>high</sup> prostate cancer cell lines. hTERT<sup>high</sup> cells exhibit CSC characteristics, such as sphere formation and elevated expression of CSC markers<sup>78</sup>. Various CSC markers are often directly regulated by the WNT/ $\beta$ -Catenin signaling axis. Dysregulated WNT signaling enhances CD44 and ALDH1A expression at the mRNA and protein levels<sup>79</sup>. miR-605, a microRNA inhibiting WNT signaling through Keratin 5 (KRT5), decreases the proliferation, migration, and invasion of PCSCs<sup>80</sup>.

### Hippo signaling


The Hippo signaling axis consists of highly conserved kinases acting in a cascade (MST1/2 and LATS1/2) and the downstream effector proteins YAP and TAZ. This signaling pathway is crucial for cellular homeostasis and tissue regeneration by stem cell regulation. Dysregulation of this pathway is intrinsically associated with tumor development, growth, and progression by CSC enrichment<sup>81</sup>. ANKHD1, a positive regulator of YAP1, is overexpressed in prostate cancer cells. Silencing of ANKHD1 leads to the downregulation of YAP1 and decreases prostate cancer cell growth and progression<sup>82</sup>. YAP1 also regulates the self-renewal property of prostate cancer cells and is negatively regulated by AR *via* YAP1 promoter methylation. ADT leads to the loss of function of AR, thus activating YAP1 and inducing CSC-like characteristics<sup>83</sup>. Silencing of TAZ, another core downstream effector of the Hippo pathway, decreases colony formation ability, CSC expression, and overall stemness in PCSCs<sup>84</sup>.

### Interaction between PCSCs and the tumor microenvironment (TME)

Genetic or epigenetic modifications within tumor cells as well as changes in the TME (including tumor cells, tumor stromal cells, and the non-cellular components of the extracellular matrix), facilitate tumor formation, maintenance, and progression<sup>85</sup> (**Figure 4**). Tumor cells are considered the main TME component because they use various cellular, non-cellular, and non-malignant processes for their tumorigenesis during every stage of cancer development and metastasis<sup>59,60</sup>.

Tumor cells can undergo EMT, wherein they lose their epithelial features, such as expression of E-cadherin and  $\beta$ -catenin, and acquire mesenchymal characteristics that increase the levels of N-cadherin and Vimentin<sup>86</sup>. EMT is associated with various events in the TME, such as tumor initiation, progression, cell migration, invasiveness, stemness, and resistance to therapy<sup>87</sup>. Recent findings suggest that, in prostate cancer, several common somatic mutations allow cancer cells to evade immunotherapy through modulation of the TME<sup>88</sup>. CSCs reside in their own “CSC niches” consisting of stromal cells, immune cells, growth factors, hypoxic areas, and extracellular matrix. The TME plays a critical role in maintaining the CSC population<sup>89</sup>. One important component of the TME is cancer-associated fibroblasts (CAFs), which regulate the tumorigenicity of various cancers, including prostate cancer. CAFs have been reported to enhance the gland-forming ability of PCSCs<sup>90</sup>. Furthermore, prostate carcinoma cells undergoing CAF-mediated EMT show elevated expression of CSC markers associated with the aggressiveness and metastasis of tumors. Consequently, treatments aimed at decreasing tumor growth and spread to secondary organs may be developed by limiting CAF-mediated EMT<sup>91</sup>.

Adipose tissues in the TME are involved in carcinogenesis, tumor progression, and metastasis. Moreover, adipocyte-secreted adipokines/cytokines play important roles in maintaining the CSC population<sup>92</sup>. Adipocytes co-cultured with prostate cancer cells secrete cysteine proteases, such as cathepsin B, and enhance the self-renewal property of CSCs<sup>93</sup>. The most abundant infiltrative immune cell population, tumor-associated macrophages (TAMs), account for 30%–50% of the tumor mass in the TME<sup>94</sup>. TAM-secreted CCL5 promotes the self-renewal ability of PCSCs, and prostate cancer invasion, EMT, and metastasis by stimulating the  $\beta$ -catenin/STAT3 pathway<sup>95</sup>. The rapid growth of cancer cells within the TME creates a hypoxic microenvironment. Therefore, the hypoxia-inducible factor 1 $\alpha$  (HIF-1 $\alpha$ ) is activated in response to hypoxia in the TME. HIF-1 $\alpha$  has been found to promote CSC populations in various cancers, including breast, bladder, and prostate cancer<sup>96-98</sup>. Marhold et al.<sup>99</sup> have demonstrated that HIF-1 $\alpha$  is involved in regulating mTOR signaling, survival, and metastasis of PCSCs. Hence, inhibition of this signaling pathway or HIF-1 $\alpha$  may serve as potential therapeutic targets for PCSCs. CD133-positive PCSCs under hypoxic conditions stimulate HIF-1 $\alpha$  gene expression, which is associated with an increase in N-Cadherin expression that leads to EMT and promotes tumor cell migration. Detailed mechanistic investigation



**Figure 4** Roles of the tumor microenvironment in the regulation of cancer stem cells. The tumor microenvironment is selectively hypoxic and contains cancer-associated fibroblasts, immune cells, and adipose tissue. In the hypoxic region, HIF-1 $\alpha$  regulates mTOR signaling. Cancer-associated fibroblasts enhance the expression of various stem cell markers. Adipose tissue secretes cytokines such as cathepsin B (CTSB). Immune cells activate various pathways, such as  $\beta$ -catenin and STAT3 signaling.

of how regulation of CD133 in PCSCs leads to tumor progression is expected to provide a new therapeutic approach<sup>100</sup>.

## Metabolic reprogramming in prostate cancer and PCSCs

The major metabolic pathways are glycolysis, oxidative phosphorylation (OXPHOS), the tricarboxylic acid (TCA) cycle, glycogenolysis, lipogenesis, and the urea cycle. Cancer cells exhibit a transition in their metabolic needs; high demands for glucose must be met to enable survival, and additional nutrition is required<sup>101,102</sup>. This transition is called metabolic reprogramming. The metabolic reprogramming in heterogeneous cancer cells orchestrates genetic changes and/or epigenetic

modifications<sup>103</sup>. The normal prostate gland synthesizes and secretes fluids that nourish and protect sperm by AR signaling-mediated processes. The AR is a nuclear hormone receptor transcription factor<sup>104,105</sup>. Acinar epithelial cells store zinc, thus inhibiting mitochondrial aconitase (ACO2), an enzyme catalyzing citrate oxidation, and blocking the entry of citrate into the TCA cycle<sup>106</sup>. Luminal cells secrete citrate as prostatic fluid to meet energy needs and support sperm viability through calcium chelation. In contrast, citrate is used in the TCA cycle primarily for energy production in other tissues<sup>107</sup>.

Metabolic reprogramming engages various metabolic pathways that support anabolic needs during cell proliferation and growth. The substantial shifts in nucleotide, amino acid, and lipid metabolism are due to genetic alterations in cancer cells. PCSCs exhibit low glycolysis, OXPHOS, and TCA, owing to

their quiescent state<sup>108</sup>. Growth factors interact with tyrosine kinase receptors and activate the PI3K and AKT signaling pathways. This signaling cascade reprograms metabolism to support the anabolic requirements of cancer cells by reinforcing the activity of metabolic enzymes and nutrient transporters<sup>109-111</sup>. For example, genes such as c-Myc and KRAS often bear mutations affecting cellular metabolism in prostate cancer. Therefore, metabolic pathways (OXPHOS, amino acids, and lipid metabolism), AR signaling, neuroendocrine metabolism, Myc, and epigenetics drive metabolic reprogramming in prostate cancer and PCSCs.

## Prostate cancer and PCSC metabolism

### OXPHOS metabolism

Ample evidence has indicated that PCSCs, in contrast to non-PCSCs, use OXPHOS as an energy source. PCSCs preferentially use glucose to synthesize pyruvate, which is fed into the TCA cycle, whereas non-PCSCs show Warburg-like effects. Therefore, OXPHOS plays a crucial role in PCSC self-renewal and survival. PCSCs exhibit a metabolic switch to meet energy demands under physiological changes. PCSCs evade stress through chemoresistance, owing to their quiescent state. During glucose deprivation, PCSCs rely on OXPHOS to escape metabolic stress. Mass spectrometry has revealed high ACO<sub>2</sub>, fumarate hydrates, malate dehydrogenase-2, citrate synthase, and oxoglutarate dehydrogenase in prostate tumors<sup>112</sup>. A transcriptomic study performing metabolite analysis has shown higher levels of malate, succinate, and fumarate in prostate tumors than in adjacent non-cancerous tissue<sup>113</sup>. This finding suggests that the early stages of prostate cancer are more dependent on OXPHOS than aerobic glycolysis.

### Amino acid metabolism

Over the past 2 decades, many amino acids have been found to affect prostate cancer metabolism. AR signaling facilitates amino acid uptake by L-type amino acid transporters (LAT1 and LAT3), such as tryptophan, leucine, tyrosine, phenylalanine, and arginine<sup>114</sup>. Glutamine uptake and assimilation are coordinated by the overexpression of neutral amino acid transporters (ASCT1 and ASCT2). Glutamine is a crucial amino acid providing building blocks for TCA cycle metabolites and NADPH. The inhibition of these transporters prevents prostate cancer growth. These expression levels of these

transporters could be helpful in diagnostic imaging to monitor prostate cancer progression in patients<sup>114,115</sup>. Androgen deprivation, an essential part of prostate cancer treatment, causes shrinkage of the normal prostate gland to 90% of its original size, owing to the loss of luminal cells<sup>116</sup>. Preclinical studies in LNCaP cells have shown an increase in ASCT2 expression in response to androgen treatment, thus enhancing the uptake of Fluciclovine, a leucine analog. Fluciclovine has been used in clinical trials to localize recurrent prostate cancer and prostatic metastases<sup>117,118</sup>. Ongoing AR-mediated amino acid metabolism research might provide new therapeutic approaches for the management of prostate cancer.

### Lipid metabolism

Lipids substantially contribute to the progression of prostate cancer<sup>25</sup>. Lipogenesis produces signaling molecules that serve as building blocks for lipid bilayers and cholesterol, thus enhancing intratumoral androgen synthesis<sup>119-121</sup>. The loss of PTEN in prostate cancer is associated with cholesterol accumulation in lipid droplets, thereby supporting tumor growth<sup>122</sup>. Moreover, PET agents, such as <sup>11</sup>C acetate and <sup>11</sup>C choline, involve lipid metabolism during prostate cancer metastasis. Expression of  $\alpha$ -methyl acyl-CoA racemase (AMACR) is elevated and subsequently induces the fatty acid oxidation, an energy source in prostate cancer, independently of AR-mediated signaling<sup>123-127</sup>. Thus, a balance between lipid biosynthesis and fatty acid oxidation is critical for the survival and growth of prostate cancer. Dysregulation of the PI3K/AKT pathway leads to the overexpression of lipogenic enzymes and fatty acid synthetic enzymes in prostate cancer<sup>128,129</sup>. The ONCOMINE database has revealed differential expression of genes associated with lipid metabolism as well as fatty acid and cholesterol metabolism<sup>130</sup>. Cholesterol metabolism is essential for prostate cancer development. Circulating lipid droplets contain cholesterol esters that directly correlate with prostate cancer aggressiveness<sup>122</sup>. Therefore, inhibition of the cholesterol acetyltransferase enzyme (acetyl-CoA) has been used to block prostate cancer cell proliferation and invasion<sup>131</sup>. Loss of PTEN results in the hyperactivation of PI3K/AKT signaling, thereby activating lipid metabolism by upregulating SREBP-2 and low-density lipoprotein receptors<sup>132</sup>. The accumulation of cholesteryl esters is balanced by the action of transcription factors such as SREBP-2 and liver-X receptor (LXR). This accumulation is promoted by AR and AKT, which activate SREBP-2 and inactivate LXR. Statins, which are clinically

used to regulate cholesterol, can also inhibit prostate cancer progression. Multiple reports have demonstrated the effect of statin therapy against prostate cancer mortality, owing to a decrease in PSA<sup>133,134</sup>. Further research on the role of statins in understanding the mechanism of prostate cancer progression may identify novel therapeutic targets for managing this cancer.

### AR-driven prostate cancer metabolism

The epithelial tissue of the prostate gland secretes testosterone, which is transformed into dihydrotestosterone (DHT) by 5 $\alpha$ -reductase. The DHT then binds AR in the cytoplasm. The bound AR translocates into the nucleus and acts as a transcription factor regulating the expression of many genes, including KLK2/3 and NKX3-1<sup>135</sup>. Testosterone also promotes the synthesis of citrate and regulates the expression of zinc transporter (SLC39A1) and aspartate transporter (SLC1A1)<sup>108,136</sup>. The oncogenic metabolic reprogramming shifts to OXPHOS and the loss of zinc transporters in prostate tumors. The major zinc transporters encoded by SLC39 transporter sub-families are responsible for zinc absorption. Zinc depletion inhibits mitochondrial ACO2 and restores the TCA cycle. In malignant prostate cancer, the levels of citrate and zinc are lower than those in non-malignant cells. The hyperactive AR drives OXPHOS and lipogenesis, thereby promoting proliferation<sup>137,138</sup>. The AR also regulates the expression of glucose transporter (GLUT1), hexokinase 1/2 (HK1 and HK2), and glucose 6-phosphate dehydrogenase (G6PD), thereby regulating glycolysis, the pentose phosphate pathway, and lipogenesis<sup>139,140</sup>.

### NEPC metabolism

NEPC is an aggressive form of prostate cancer that develops because of selective pressure due to androgen removal. It is characterized by enhanced expression of neuroendocrine markers, such as neuron-specific enolase, chromogranin-A, and synaptophysin, along with decreased AR signaling<sup>141</sup>. Genetic loss of RB1 and TP53 and upregulation of MYCN and AURKA have been observed in NEPC. The loss of RN1 and TP53 further activates the pluripotency transcription factor SOX2 and epigenetic modifier EZH2<sup>142,143</sup>. The epigenetic changes are coupled to altered metabolism; for example, glycolysis produces pyruvate, which serves as a substrate for acetyl-CoA and consequently regulates histone acetyltransferase

enzyme activity<sup>144</sup>. Histone lysine demethylase (KDM8) expression is upregulated, thus altering metabolism to favor aerobic glycolysis<sup>145</sup>. During treatment or disease progression, protein kinase C (PKC) $\lambda$  is inhibited. Downregulation of PKC $\lambda$  leads to increased serine biosynthesis *via* a mTORC1/ATF4-regulated pathway. The metabolic reprogramming increases cellular proliferation and S-adenosyl methionine, thereby inducing epigenetic changes that facilitate the further progression of NEPC<sup>146</sup>. NEPC is characterized by an increase in glycolysis and enhanced glutamine uptake, leading to increased pyruvate and acetyl-CoA production. Increased glycolysis and MCT-4-mediated lactic acid production and secretion are the most notable and clinically relevant metabolic characteristics in NEPC<sup>12</sup>.

### Myc-dependent reprogramming

Myc plays a crucial role in metabolic reprogramming because of its enhanced expression in prostate cancer and PCSCs. It regulates the glutamine transporter genes SLC1A4 and SLC1A5, thereby contributing to glutamine metabolism. It also regulates glucose metabolism *via* glucose transporter GLUT1, hexokinase 2 (HK2), enolase 1, lactate dehydrogenase A, and phosphofructokinase (PFK1)<sup>147</sup>. Therefore, Myc can be targeted to inhibit the growth of PCSCs<sup>148,149</sup>.

## Therapeutic strategies targeting PCSCs

Prostate cancer is a major malignancy in men, and prior studies have improved the understanding of the molecular basis of carcinogenesis, early diagnosis, and effective therapy. ADT is used primarily for prostate cancer treatment. Although ADT is effective, it targets only prostate cancer cells that are androgen-dependent; in most patients, the tumor then progresses to metastatic castration-resistant prostate cancer<sup>150</sup>. Furthermore, poor prognosis is often observed in such cases.

Patients with prostate cancer are treated with ADT in early disease stages<sup>151</sup>. Later, ADT and chemotherapy are given to patients with CRPCs to inhibit metastasis by targeting fast-growing prostate cancer cells<sup>152,153</sup>. The PCSCs show resistance to chemotherapy, hormone therapy, and radiotherapy. Therefore, prostate cancer may relapse because of the presence of undifferentiated CSCs. Current treatments usually destroy differentiated and rapidly dividing prostate

cancer cells, thus leaving a resistant CSC subpopulation as a result of the heterogeneity of prostate cancer<sup>154-156</sup>. Various mechanisms primarily based on AR signaling may explain the establishment of CRPC. Targeting of AR signaling in prostate cancer cells has been the prime focus<sup>44,157-159</sup>. A recent report has shown that SOX2 plays a crucial role in the survival and pluripotency of PCSCs. It also promotes tumor aggressiveness. Moreover, SOX2-positive PCSCs have higher Gleason scores than SOX2-negative PCSCs. In addition, AR signaling suppresses SOX2 expression in CRPCs, and this effect can be reversed with anti-androgen factor exposure. SOX2 overexpression in castrated nude mice increases the tumor formation<sup>160</sup>. Thus, the relapse of prostate cancer to castration-resistant-SOX2 expressing tumors might be due to the constitutive expression of AR splice variant receptors that are deficient in the ligand binding domain<sup>161-164</sup>.

Another report has revealed that ADT increases the expression of AR and AR splicing variants and enriches the PCSC population<sup>165</sup>. Therefore, more advanced and effective therapy is required to target PCSCs. Metformin has been used as an anti-cancer therapy because it affects CSCs in various cancer types, including prostate cancer. It acts on mitochondria and decreases ATP synthesis *via* oxidative phosphorylation, an energy hub for PCSCs<sup>166-170</sup>. Therefore, Metformin enhances sensitivity toward PCSCs when applied in combination with existing therapies. It also increases drug efficacy and inhibits relapse. Bilen et al.<sup>171</sup> have reported the treatment efficacy of Metformin alone or in combination with other drugs. This study has further proposed that Metformin and/or Zylamend might target PCSCs and tumor niches and maintain a dormant tumor state.

Additionally, Iliopoulos et al.<sup>168</sup> have highlighted the role of Metformin in combination with other drugs to prevent relapse by using prostate cancer xenograft models. Moreover, various studies have shown that phytochemicals or plant extracts can eliminate CSC populations in multiple cancers, including prostate cancer<sup>172,173</sup>. Among these natural compounds, curcumin has been found to be effective against prostate cancer. It affects cell proliferation through WNT signaling in AR-dependent and independent prostate cancer cell lines<sup>174</sup>. Furthermore, curcumin targets CD133<sup>hi</sup>/CD44<sup>+hi</sup> prostate cancer cells and decreases the PCSC population by inhibiting stemness-associated genes and preventing drug resistance<sup>175</sup>. Therefore, investigations have provided a deeper understanding of the association of PCSCs with tumorigenesis. PCSCs have also been reported to downregulate the expression of

immunogenic markers such as HLA1 and PD1 while upregulating IL-4, thus providing a better understanding of the immune evasion abilities of undifferentiated cells<sup>176</sup>. Active immunotherapy by activating endogenous T cells to cancer *via* tumor-associated antigens can be performed with vaccines such as whole cell, peptide, or dendritic cell (DC) vaccines. Moreover, DCs, along with irradiated PCSCs, have a more targeted tumor response than DCs with irradiated non-CSCs. A DC-CSC-based vaccine has been found to inhibit mouse tumor growth<sup>177</sup>. Several clinical trials are in the pipeline to verify the effectiveness of DNA-based immunization in inducing antigen-specific T cells. In human CRPC, both prostatic acid phosphatase and PSA have been used as DNA-based vaccination targets in a randomized phase II trial<sup>178,179</sup>. Further studies are required to determine the key signaling regulators involved in the self-renewal and survival of PCSCs. The understanding gained should enable better therapeutic strategies to eliminate tumors, drug resistance, and relapse and increase patient survival.

## Conclusions


Mounting evidence in recent years indicates that CSCs are at the center of prostate cancer progression, metastasis, drug resistance, and, most importantly, relapse. In prostate cancer, disease recurrence leads to the development of CRPC. PCSCs can be isolated and enriched through multiple methods based on cell surface markers such as CD44, CD133, and  $\alpha 2\beta 1$  integrin; intracellular markers including Yamanaka factors and ABCG members; self-renewal; AR and PSA expression; and even cell size. Subsequent studies, including those performing isolation of PCSCs, have provided extensive insight into the regulatory mechanisms and signaling pathways involved in the induction and maintenance of CSCs. The various signaling pathways involved in PCSC induction and maintenance include the PI3K/AKT, RAS/MAPK, Hedgehog, Notch, WNT, and Hippo pathways. Through an intricate and extensive network of crosstalk between signaling molecules and various metabolic regulators, these pathways confer self-renewal ability, EMT potential, and drug resistance on prostate cancer cells.

The metabolic reprogramming in cancer cells, particularly in PCSCs, with reduced glycolysis, OXPHOS, and TCA, leads to the deregulation of downstream signaling, such as the PI3K/AKT axis. These pathways are associated with CSC maintenance. Thus, metabolic reprogramming and crosstalk between cellular signaling pathways can be concluded to promote



stem-like characteristics, such as self-renewal, drug resistance, and EMT, in prostate cancer cells. This crosstalk between signaling and metabolic pathways provides molecular targets for developing novel therapeutics against PCSCs.

The presence of PCSCs, the EMT in prostate cancer cells, and CRPC are intrinsically connected. Emerging evidence indicates that EMT and the CSC phenomenon together contribute to the progression of prostate cancer in a hormone-independent manner. The ADT-mediated changes in the signaling pathways in CSCs, and in all cancer cells in general, lead to changes in the TME. The modified TME, in turn, regulates those signaling pathways within cancer cells (Figure 5). Reversing the EMT process or CSCs in prostate cancer could regress the development of CRPC. Thus, targeting the signaling crosstalk and reprogrammed metabolic pathways is a viable therapeutic approach for the better management of advanced prostate cancer.



**Figure 5** Androgen deprivation therapy leads to an aggressive prostate cancer type called castration-resistant prostate cancer (CRPC). Androgen deprivation therapy stimulates CSC pathways and the EMT process, thus leading to inhibition of androgen receptor (AR)-dependent pathways. However, alternative survival pathways are activated. Furthermore, angiogenic factor secretion, pro-tumorigenic cytokine secretion, TAMs, and CAFs also increase in the TME. These changes in the TME and targeted signaling pathways induce development of castration-resistant prostate cancer.

## Grant support

The fellowship of PB is supported by the Department of Biotechnology (DBT), Govt of India. The fellowship of PK is supported by the Council of Scientific and Industrial Research (CSIR), Govt. of India. The fellowship of JC is supported by the University Grants Commission (UGC), Govt. of India. This project is partly supported by BT/INF/22/SP42155/2021 from the Department of Biotechnology, Ministry of Science and Technology, Govt. of India.

## Conflict of interest statement

No potential conflicts of interest are disclosed.

## Author contributions

Conceived and designed the analysis: Suresh W Gosavi, Rajesh N Gacche, Gopal C Kundu.

Collected the data: Pinaki Banerjee, Prachi Kapse, Shehnaz Siddique, Moumita Kundu, Diksha Malhotra, Gopal C Kundu.

Wrote the paper: Pinaki Banerjee, Prachi Kapse, Shehnaz Siddique, Moumita Kundu, Jasoda Choudhari, Varshasnata Mohanty, Diksha Malhotra, Gopal C Kundu.

## References

- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021; 71: 209-49.
- Marx A, Koopmann L, Höflmayer D, Büscheck F, Hube-Magg C, Steurer S, et al. Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer. *Cancer Biol Med.* 2021; 18: 245-55.
- Collins AT, Maitland NJ. Prostate cancer stem cells. *Eur J Cancer.* 2006; 42: 1213-8.
- Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell.* 2000; 100: 57-70.
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell.* 2011; 144: 646-74.
- Fouad Y, Aanei C. Revisiting the hallmarks of cancer. *Am J Cancer Res.* 2017; 7: 1016-36.
- Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. *J Clin Oncol.* 2008; 26: 2862-70.
- Wang ZA, Shen MM. Revisiting the concept of cancer stem cells in prostate cancer. *Oncogene.* 2011; 30: 1261-71.

9. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. *Cell*. 2009; 138: 822-9.
10. Marotta LLC, Polyak K. Cancer stem cells: a model in the making. *Curr Opin Genet Dev*. 2009; 19: 44-50.
11. Menendez J, Joven J, Cufi S, Corominas-Faja B, Oliveras-Ferreros C, Cuyàs E, et al. The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. *Cell Cycle*. 2013; 12: 1166-79.
12. Ahmad F, Cherukuri MK, Choyke PL. Metabolic reprogramming in prostate cancer. *Br J Cancer*. 2021; 125: 1185-96.
13. Yun EJ, Lo UG, Hsieh JT. The evolving landscape of prostate cancer stem cell: therapeutic implications and future challenges. *Asian J Urol*. 2016; 3: 203-10.
14. Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. *Genes Dev*. 2018; 32: 1105-40.
15. Romańska-Knight H, Abel P. REVIEW ARTICLES Prostate cancer stem cells. *Cent Eur J Urol*. 2011; 64: 196-200.
16. Zhang D, Zhao S, Li X, Kirk JS, Tang DG. Prostate luminal progenitor cells in development and cancer. *Trends Cancer*. 2018; 4: 769-83.
17. Avgustinova A, Benitah SA. The epigenetics of tumour initiation: cancer stem cells and their chromatin. *Curr Opin Genet Dev*. 2016; 36: 8-15.
18. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. *Nat Rev Clin Oncol*. 2017; 14: 611-29.
19. Yun EJ, Zhou J, Lin CJ, Hernandez E, Fazli L, Gleave M, et al. Targeting cancer stem cells in castration-resistant prostate cancer. *Clin Cancer Res*. 2016; 22: 670-9.
20. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. *J Cell Sci*. 2004; 117: 3539-45.
21. Taylor RA, Toivanen R, Frydenberg M, Pedersen J, Harewood L, Collins AT, et al. Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status. *Stem Cells*. 2012; 30: 1087-96.
22. Liu AY, Nelson PS, van den Engh G, Hood L. Human prostate epithelial cell-type cDNA libraries and prostate expression patterns. *Prostate*. 2002; 50: 92-103.
23. Kyprianou N, Isaacs JT. Identification of a cellular receptor for transforming growth factor- $\beta$  in rat ventral prostate and its negative regulation by androgens\*. *Endocrinology*. 1988; 123: 2124-31.
24. De Marzo AM, Meeker AK, Epstein JI, Coffey DS. Prostate stem cell compartments. *Am J Pathol*. 1998; 153: 911-9.
25. Choi N, Zhang B, Zhang L, Ittmann M, Xin L. Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. *Cancer Cell*. 2012; 21: 253-65.
26. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell of origin for human prostate cancer. *Science*. 2010; 329: 568-71.
27. Smith BA, Sokolov A, Uzunangelov V, Baertsch R, Newton Y, Graim K, et al. A basal stem cell signature identifies aggressive prostate cancer phenotypes. *Proc Natl Acad Sci*. 2015; 112: E6544-52.
28. Liu AY, True LD, LaTray L, Nelson PS, Ellis WJ, Vessella RL, et al. Cell-cell interaction in prostate gene regulation and cytodifferentiation. *Proc Natl Acad Sci*. 1997; 94: 10705-10.
29. Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, Schneider-Broussard R, et al. Prostate cancer stem/progenitor cells: identification, characterization, and implications: prostate cancer stem/progenitor cells. *Mol Carcinog*. 2007; 46: 1-14.
30. Wang X, de Julio MK, Economides KD, Walker D, Yu H, Halili MV, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. *Nature*. 2009; 461: 495-500.
31. Wang JCY. Good cells gone bad: the cellular origins of cancer. *Trends Mol Med*. 2010; 16: 145-51.
32. Pomerantz MM, Qiu X, Zhu Y, Takeda DY, Pan W, Baca SC, et al. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. *Nat Genet*. 2020; 52: 790-9.
33. Yamada Y, Beltran H. Clinical and biological features of neuroendocrine prostate cancer. *Curr Oncol Rep*. 2021; 23: 15.
34. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. *Nature*. 2010; 467: 1109-13.
35. Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR, et al. The PSA- $\alpha$  prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. *Cell Stem Cell*. 2012; 10: 556-69.
36. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44<sup>+</sup>  $\alpha$ 2 $\beta$ 1<sup>+</sup> cell population is enriched in tumor-initiating cells. *Cancer Res*. 2007; 67: 6796-805.
37. Shibata M, Shen MM. Stem cells in genetically-engineered mouse models of prostate cancer. *Endocr Relat Cancer*. 2015; 22: T199-208.
38. Lo UG, Lee CF, Lee MS, Hsieh JT. The role and mechanism of epithelial-to-mesenchymal transition in prostate cancer progression. *Int J Mol Sci*. 2017; 18: 2079.
39. Drago D, Andolfo A, Mosca E, Orro A, Nocera L, Cucchiara V, et al. A novel expressed prostatic secretion (EPS)-urine metabolomic signature for the diagnosis of clinically significant prostate cancer. *Cancer Biol Med*. 2021; 18: 604-15.
40. Schröder F, Crawford ED, Axcrone K, Payne H, Keane TE. Androgen deprivation therapy: past, present and future: androgen deprivation therapy: past, present and future. *BJU Int*. 2012; 109: 1-12.
41. Tang DG. Understanding and targeting prostate cancer cell heterogeneity and plasticity. *Semin Cancer Biol*. 2022; 82: 68-93.
42. Parol-Kulczyk M, Gzil A, Ligmanowska J, Grzanka D. Prognostic significance of SDF-1 chemokine and its receptors CXCR4 and CXCR7 involved in EMT of prostate cancer. *Cytokine*. 2022; 155: 778.
43. Joesting MS, Perrin S, Elenbaas B, Fawell SE, Rubin JS, Franco OE, et al. Identification of *SFRP1* as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. *Cancer Res*. 2005; 65: 10423-30.

44. Shiota M, Fujimoto N, Matsumoto T, Tsukahara S, Nagakawa S, Ueda S, et al. Differential impact of TGF $\beta$ 1 variation by metastatic status in androgen-deprivation therapy for prostate cancer. *Front Oncol.* 2021; 11: 697955.
45. Agarwal JR, Zambidis ET. The role of an NF $\kappa$ B-STAT3 signaling axis in regulating the induction and maintenance of the pluripotent state. In: Atwood CS, Meethal SV, editors. *Pluripotent stem cell biology - advances in mechanisms, methods and models.* InTech; 2014.
46. Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. *Nat Rev Urol.* 2018; 15: 271-86.
47. Skvortsov S, Skvortsova II, Tang DG, Dubrovskaya A. Concise review: prostate cancer stem cells: current understanding. *Stem Cells.* 2018; 36: 1457-74.
48. Liu WH, Qian NS, Li R, Dou KF. Replacing Hoechst33342 with Rhodamine123 in isolation of cancer stem-like cells from the MHCC97 cell line. *Toxicol In Vitro.* 2010; 24: 538-45.
49. Vidal SJ, Quinn SA, de la Iglesia-Vicente J, Bonal DM, Rodriguez-Bravo V, Firpo-Betancourt A, et al. Isolation of cancer stem cells from human prostate cancer samples. *J Vis Exp.* 2014; 85: 51332.
50. Sheng X, Li Z, Wang DL, Li WB, Luo Z, Chen KH, et al. Isolation and enrichment of PC-3 prostate cancer stem-like cells using MACS and serum-free medium. *Oncol Lett.* 2013; 5: 787-92.
51. Kim WT, Ryu CJ. Cancer stem cell surface markers on normal stem cells. *BMB Rep.* 2017; 50: 285-98.
52. Tang B, Raviv A, Esposito D, Flanders KC, Daniel C, Nghiem BT, et al. A flexible reporter system for direct observation and isolation of cancer stem cells. *Stem Cell Rep.* 2015; 4: 155-69.
53. Thiagarajan PS, Hitomi M, Hale JS, Alvarado AG, Otvos B, Sinyuk M, et al. Development of a fluorescent reporter system to delineate cancer stem cells in triple-negative breast cancer. *Stem Cells.* 2015; 33: 2114-25.
54. Jeter CR, Liu B, Liu X, Chen X, Liu C, Calhoun-Davis T, et al. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. *Oncogene.* 2011; 30: 3833-45.
55. Chen X, Rycak K, Liu X, Tang DG. New insights into prostate cancer stem cells. *Cell Cycle.* 2013; 12: 579-86.
56. Li Q, Rycak K, Chen X, Tang DG. Cancer stem cells and cell size: a causal link? *Semin Cancer Biol.* 2015; 35: 191-9.
57. Chen YC, Ingram PN, Fouladdel S, McDermott SP, Azizi E, Wicha MS, et al. High-throughput single-cell derived sphere formation for cancer stem-like cell identification and analysis. *Sci Rep.* 2016; 6: 27301.
58. Matsui WH. Cancer stem cell signaling pathways. *Medicine (Baltimore).* 2016; 95: S8-19.
59. Wu J, Cang S, Liu C, Ochiai W, Chiao JW. Development of human prostate cancer stem cells involves epigenomic alteration and PI3K/AKT pathway activation. *Exp Hematol Oncol.* 2020; 9: 12.
60. Dubrovskaya A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. *Proc Natl Acad Sci.* 2009; 106: 268-73.
61. Chang L, Graham PH, Hao J, Ni J, Buccini J, Cozzi PJ, et al. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. *Cell Death Dis.* 2013; 4: e875-e875.
62. Ma B, Shao H, Jiang X, Wang Z, Wu CC, Whaley D, et al. Akt isoforms differentially provide for chemoresistance in prostate cancer. *Cancer Biol Med.* 2021; 19: 635-50.
63. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. *Oncogene.* 2007; 26: 3279-90.
64. Rybak AP, Ingram AJ, Tang D. Propagation of human prostate cancer stem-like cells occurs through EGFR-mediated ERK activation. *PLoS ONE.* 2013; 8: e61716.
65. Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, et al. *Pten* loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. *Cancer Res.* 2012; 72: 1878-89.
66. Ko J, Meyer AN, Haas M, Donoghue DJ. Characterization of FGFR signaling in prostate cancer stem cells and inhibition via TKI treatment. *Oncotarget.* 2021; 12: 22-36.
67. Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, Gao AC. Stat3 activation in prostatic carcinomas. *The Prostate.* 2002; 51: 241-6.
68. Schroeder A, Herrmann A, Cherryholmes G, Kowolik C, Buettner R, Pal S, et al. Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. *Cancer Res.* 2014; 74: 1227-37.
69. Kroon P, Berry PA, Stower MJ, Rodrigues G, Mann VM, Simms M, et al. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. *Cancer Res.* 2013; 73: 5288-98.
70. Carvalho FLE, Simons BW, Eberhart CG, Berman DM. Notch signaling in prostate cancer: a moving target: notch signaling in prostate cancer. *Prostate.* 2014; 74: 933-45.
71. Espinoza I, Miele L. Deadly crosstalk: notch signaling at the intersection of EMT and cancer stem cells. *Cancer Lett.* 2013; 341: 41-5.
72. Cochrane C, Szczepny A, Watkins D, Cain J. Hedgehog signaling in the maintenance of cancer stem cells. *Cancers.* 2015; 7: 1554-85.
73. Shaw A, Bushman W. Hedgehog signaling in the prostate. *J Urol.* 2007; 177: 832-8.
74. Datta S, Datta MW. Sonic Hedgehog signaling in advanced prostate cancer. *Cell Mol Life Sci.* 2006; 63: 435-48.
75. Acikgoz E, Mukhtarova G, Alpay A, Avci CB, Bagca BG, Oktem G. Sonic hedgehog signaling is associated with resistance to zoledronic acid in CD133<sup>high</sup>/CD44<sup>high</sup> prostate cancer stem cells. *Mol Biol Rep.* 2021; 48: 3567-78.
76. Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. *Oncogene.* 2017; 36: 1461-73.
77. Bisson I, Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. *Cell Res.* 2009; 19: 683-97.
78. Zhang K, Guo Y, Wang X, Zhao H, Ji Z, Cheng C, et al. WNT/ $\beta$ -Catenin directs self-renewal symmetric cell division of hTERT<sup>high</sup> prostate cancer stem cells. *Cancer Res.* 2017; 77: 2534-47.
79. Murillo-Garzon V, Kypta R. WNT signalling in prostate cancer. *Nat Rev Urol.* 2017; 14: 683-96.

80. Du H, Wang X, Dong R, Hu D, Xiong Y. miR-601 inhibits proliferation, migration and invasion of prostate cancer stem cells by targeting KRT5 to inactivate the Wnt signaling pathway. *Int J Clin Exp Pathol.* 2019; 12: 4361-79.
81. Mo J, Park HW, Guan K. The Hippo signaling pathway in stem cell biology and cancer. *EMBO Rep.* 2014; 15: 642-56.
82. Machado-Neto JA, Lazarini M, Favaro P, Franchi GC, Nowill AE, Saad STO, et al. ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells. *Exp Cell Res.* 2014; 324: 137-45.
83. Jiang N, Ke B, Hjort-Jensen K, Iglesias-Gato D, Wang Z, Chang P, et al. YAP1 regulates prostate cancer stem cell-like characteristics to promote castration resistant growth. *Oncotarget.* 2017; 8: 115054-67.
84. Liu N, Mei L, Fan X, Tang C, Ji X, Hu X, et al. Phosphodiesterase 5/ protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway. *Cancer Lett.* 2016; 378: 38-50.
85. Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, et al. Tumor microenvironment complexity and therapeutic implications at a glance. *Cell Commun Signal.* 2020; 18: 59.
86. Nieto MA, Huang RYJ, Jackson RA, Thiery JP. EMT: 2016. *Cell.* 2016; 166: 21-45.
87. Craene BD, Bex G. Regulatory networks defining EMT during cancer initiation and progression. *Nat Rev Cancer.* 2013; 13: 97-110.
88. Melo CM, Vidotto T, Chaves LP, Lautert-Dutra W, dos Reis RB, Squire JA. The role of somatic mutations on the immune response of the tumor microenvironment in prostate cancer. *Int J Mol Sci.* 2021; 22: 9550.
89. Lau EYT, Ho NPY, Lee TKW. Cancer stem cells and their microenvironment: biology and therapeutic implications. *Stem Cells Int.* 2017; 2017: 3714190.
90. Liao CP, Adisetiyo H, Liang M, Roy-Burman P. Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells. *Cancer Res.* 2010; 70: 7294-303.
91. Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L, et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. *Cancer Res.* 2010; 70: 6945-56.
92. Fantuzzi G. Adipose tissue, adipokines, and inflammation. *J Allergy Clin Immunol.* 2005; 115: 911-9.
93. Tang KD, Liu J, Jovanovic L, An J, Hill MM, Vela I, et al. Adipocytes promote prostate cancer stem cell self-renewal through amplification of the cholecystokinin autocrine loop. *Oncotarget.* 2016; 7: 4939-48.
94. Chen Y, Tan W, Wang C. Tumor-associated macrophage-derived cytokines enhance cancer stem-like characteristics through epithelial-mesenchymal transition. *Onco Targets Ther.* 2018; 11: 3817-26.
95. Huang R, Wang S, Wang N, Zheng Y, Zhou J, Yang B, et al. CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating  $\beta$ -catenin/STAT3 signaling. *Cell Death Dis.* 2020; 11: 234.
96. Zhang C, Zhi WI, Lu H, Samanta D, Chen I, Gabrielson E, et al. Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells. *Oncotarget.* 2016; 7: 64527-42.
97. Bae KM, Dai Y, Vieweg J, Siemann DW. Hypoxia regulates SOX2 expression to promote prostate cancer cell invasion and sphere formation. *Am J Cancer Res.* 2016; 6: 1078-88.
98. Koukourakis ML, Kakouratos C, Kalamida D, Bampali Z, Mavropoulou S, Sivridis E, et al. Hypoxia-inducible proteins HIF1 $\alpha$  and lactate dehydrogenase LDH5, key markers of anaerobic metabolism, relate with stem cell markers and poor post-radiotherapy outcome in bladder cancer. *Int J Radiat Biol.* 2016; 92: 353-63.
99. Marhold M, Tomasich E, El-Gazzar A, Heller G, Spittler A, Horvat R, et al. HIF1 $\alpha$  Regulates mTOR signaling and viability of prostate cancer stem cells. *Mol Cancer Res.* 2015; 13: 556-64.
100. Maeda K, Ding Q, Yoshimitsu M, Kuwahata T, Miyazaki Y, Tsukasa K, et al. CD133 Modulate HIF-1 $\alpha$  expression under hypoxia in EMT phenotype pancreatic cancer stem-like cells. *Int J Mol Sci.* 2016; 17: 1025.
101. DeBerardinis RJ, Thompson CB. Cellular metabolism and disease: what do metabolic outliers teach us? *Cell.* 2012; 148: 1132-44.
102. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. *Cell Metab.* 2016; 23: 27-47.
103. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. *Sci Adv.* 2016; 2: e1600200.
104. Bader DA, Hartig SM, Putluri V, Foley C, Hamilton MP, Smith EA, et al. Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. *Nat Metab.* 2019; 1: 70-85.
105. Verze P, Cai T, Lorenzetti S. The role of the prostate in male fertility, health and disease. *Nat Rev Urol.* 2016; 13: 379-86.
106. Barron ESG, Huggins C. The metabolism of the prostate: transamination and citric acid. *J Urol.* 1946; 55: 385-90.
107. Mycielska ME, Patel A, Rizaner N, Mazurek MP, Keun H, Patel A, et al. Citrate transport and metabolism in mammalian cells: prostate epithelial cells and prostate cancer. *BioEssays.* 2009; 31: 10-20.
108. Costello LC, Liu Y, Franklin RB, Kennedy MC. Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells. *J Biol Chem.* 1997; 272: 28875-81.
109. Düvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. *Mol Cell.* 2010; 39: 171-83.
110. Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. ATP citrate lyase is an important component of cell growth and transformation. *Oncogene.* 2005; 24: 6314-22.
111. Wang W, Fridman A, Blackledge W, Connelly S, Wilson IA, Pilz RB, et al. The phosphatidylinositol 3-Kinase/Akt cassette regulates purine nucleotide synthesis. *J Biol Chem.* 2009; 284: 3521-8.
112. Latonen L, Afyounian E, Jylhä A, Nättinen J, Aapola U, Annala M, et al. Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. *Nat Commun.* 2018; 9: 1176.

113. Shao Y, Ye G, Ren S, Piao HL, Zhao X, Lu X, et al. Metabolomics and transcriptomics profiles reveal the dysregulation of the tricarboxylic acid cycle and related mechanisms in prostate cancer: metabolomics and transcriptomics profiles in prostate cancer. *Int J Cancer*. 2018; 143: 396-407.
114. Wang Q, Tiffen J, Bailey CG, Lehman ML, Ritchie W, Fazli L, et al. Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. *JNCI J Natl Cancer Inst*. 2013; 105: 1463-73.
115. Wang Q, Bailey CG, Ng C, Tiffen J, Thoeng A, Minhas V, et al. Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. *Cancer Res*. 2011; 71: 7525-36.
116. Karthaus WR, Hofree M, Choi D, Linton EL, Turkecul M, Bejnood A, et al. Regenerative potential of prostate luminal cells revealed by single-cell analysis. *Science*. 2020; 368: 497-505.
117. Savir-Baruch B, Zanoni L, Schuster DM. Imaging of prostate cancer using fluciclovine. *Urol Clin North Am*. 2018; 45: 489-502.
118. Okudaira H, Oka S, Ono M, Nakanishi T, Schuster DM, Kobayashi M, et al. Accumulation of trans-1-amino-3-[18F] Fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters. *Mol Imaging Biol*. 2014; 16: 756-64.
119. Zaidi N, Lupien L, Kuemmerle NB, Kinlaw WB, Swinnen JV, Smans K. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. *Prog Lipid Res*. 2013; 52: 585-9.
120. Clarke NW, Brown MD. The influence of lipid metabolism on prostate cancer development and progression: is it time for a closer look? *Eur Urol*. 2007; 52: 3-4.
121. Suburu J, Chen YQ. Lipids and prostate cancer. *Prostaglandins Other Lipid Mediat*. 2012; 98: 1-10.
122. Yue S, Li J, Lee SY, Lee HJ, Shao T, Song B, et al. Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. *Cell Metab*. 2014; 19: 393-406.
123. Gazi E, Gardner P, Lockyer NP, Hart CA, Brown MD, Clarke NW. Direct evidence of lipid translocation between adipocytes and prostate cancer cells with imaging FTIR microspectroscopy. *J Lipid Res*. 2007; 48: 1846-56.
124. Swinnen JV, Roskams T, Joniau S, van Poppel H, Oyen R, Baert L, et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. *Int J Cancer*. 2002; 98: 19-22.
125. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. *Prostate Cancer Prostatic Dis*. 2006; 9: 230-4.
126. Lloyd MD, Yevglevskis M, Lee GL, Wood PJ, Threadgill MD, Woodman TJ.  $\alpha$ -Methylacyl-CoA racemase (AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S. *Prog Lipid Res*. 2013; 52: 220-30.
127. Zha S, Ferdinandusse S, Denis S, Wanders RJ, Ewing CM, Luo J, et al. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. *Cancer Res*. 2003; 63: 7365-76.
128. Ahmad F, Patrick S, Sheikh T, Sharma V, Pathak P, Malgularwar PB, et al. Telomerase reverse transcriptase (TERT) - enhancer of zeste homolog 2 (EZH2) network regulates lipid metabolism and DNA damage responses in glioblastoma. *J Neurochem*. 2017; 143: 671-83.
129. Van de Sande T, Roskams T, Lerut E, Joniau S, Van Poppel H, Verhoeven G, et al. High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. *J Pathol*. 2005; 206: 214-9.
130. Guo D, Bell E, Mischel P, Chakravarti A. Targeting SREBP-1-driven lipid metabolism to treat cancer. *Curr Pharm Des*. 2014; 20: 2619-26.
131. Ayyagari VN, Wang X, Diaz-Sylvester PL, Groesch K, Brard L. Assessment of acyl-CoA cholesterol acyltransferase (ACAT-1) role in ovarian cancer progression—an in vitro study. *PLoS One*. 2020; 15: e0228024.
132. Wu X, Daniels G, Lee P, Monaco ME. Lipid metabolism in prostate cancer. *Am J Clin Exp Urol*. 2014; 2: 111-20.
133. Roy M, Kung HJ, Ghosh PM. Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. *Am J Cancer Res*. 2011; 1: 542-61.
134. Svensson RU, Parker SJ, Eichner LJ, Kolar MJ, Wallace M, Brun SN, et al. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. *Nat Med*. 2016; 22: 1108-19.
135. Prescott JL, Blok L, Tindall DJ. Isolation and androgen regulation of the human homeobox cDNA, NKX3.1. *Prostate*. 1998; 35: 71-80.
136. Lao L, Franklin RB, Costello LC. High-affinity L-aspartate transporter in prostate epithelial cells that is regulated by testosterone. *Prostate*. 1993; 22: 53-63.
137. Swinnen JV, Van Veldhoven PP, Esquet M, Heyns W, Verhoeven G. Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. *Endocrinology*. 1996; 137: 4468-74.
138. Audet-Walsh É, Yee T, McGuirk S, Vernier M, Ouellet C, St-Pierre J, et al. Androgen-dependent repression of ERR $\gamma$  reprograms metabolism in prostate cancer. *Cancer Res*. 2017; 77: 378-89.
139. Tsouko E, Khan AS, White MA, Han JJ, Shi Y, Merchant FA, et al. Regulation of the pentose phosphate pathway by an androgen receptor–mTOR-mediated mechanism and its role in prostate cancer cell growth. *Oncogenesis*. 2014; 3: e103-e103.
140. Patra KC, Hay N. The pentose phosphate pathway and cancer. *Trends Biochem Sci*. 2014; 39: 347-54.
141. Ather MH, Abbas F, Faruqui N, Israr M, Pervez S. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. *BMC Urol*. 2008; 8: 21.
142. Choi YJ, Lin CP, Ho JJ, He X, Okada N, Bu P, et al. miR-34 miRNAs provide a barrier for somatic cell reprogramming. *Nat Cell Biol*. 2011; 13: 1353-60.
143. Kareta MS, Gorges LL, Hafeez S, Benayoun BA, Marro S, Zmoos AF, et al. Inhibition of pluripotency networks by the Rb tumor suppressor restricts reprogramming and tumorigenesis. *Cell Stem Cell*. 2015; 16: 39-50.



144. Schwartzman JM, Thompson CB, Finley LWS. Metabolic regulation of chromatin modifications and gene expression. *J Cell Biol.* 2018; 217: 2247-59.
145. Wang HJ, Pochampalli M, Wang LY, Zou JX, Li PS, Hsu SC, et al. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC. *Oncogene.* 2019; 38: 17-32.
146. Reina-Campos M, Linares JF, Duran A, Cordes T, L'Hermitte A, Badur MG, et al. Increased serine and one-carbon pathway metabolism by PKC $\lambda$ /t deficiency promotes neuroendocrine prostate cancer. *Cancer Cell.* 2019; 35: 385-400.e9.
147. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. *Clin Cancer Res.* 2009; 15: 6479-83.
148. Liu R, Liu C, Zhang D, Liu B, Chen X, Rycaj K, et al. miR-199a-3p targets stemness-related and mitogenic signaling pathways to suppress the expansion and tumorigenic capabilities of prostate cancer stem cells. *Oncotarget.* 2016; 7: 56628-42.
149. Civenni G, Malek A, Albino D, Garcia-Escudero R, Napoli S, Di Marco S, et al. RNAi-Mediated silencing of myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer. *Cancer Res.* 2013; 73: 6816-27.
150. Sharifi N, Kawasaki BT, Hurt EM. Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy. *Cancer Biol Ther.* 2006; 5: 901-6.
151. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. *Nature.* 2012; 487: 239-43.
152. Semenas J, Allegrucci C, Boorjian SA, Mongan NP, Liao Persson J. Overcoming drug resistance and treating advanced prostate cancer. *Curr Drug Targets.* 2012; 13: 1308-23.
153. Ni J, Cozzi P, Hao J, Duan W, Graham P, Kearsley J, et al. Cancer stem cells in prostate cancer chemoresistance. *Curr Cancer Drug Targets.* 2014; 14: 225-40.
154. Bishop JL, Davies A, Ketola K, Zoubeidi A. Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. *Endocr Relat Cancer.* 2015; 22: R165-82.
155. Singh P, Uzgare A, Litvinov I, Denmeade SR, Isaacs JT. Combinatorial androgen receptor targeted therapy for prostate cancer. *Endocr Relat Cancer.* 2006; 13: 653-66.
156. Zhang L, Jiao M, Li L, Wu D, Wu K, Li X, et al. Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties. *J Cancer Res Clin Oncol.* 2012; 138: 675-86.
157. Njar VCO, Brodie AMH. Discovery and development of galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. *J Med Chem.* 2015; 58: 2077-87.
158. Adeniji AO, Chen M, Penning TM. AKR1C3 as a target in castrate resistant prostate cancer. *J Steroid Biochem Mol Biol.* 2013; 137: 136-49.
159. De Leon JT, Iwai A, Feau C, Garcia Y, Balsiger HA, Storer CL, et al. Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. *Proc Natl Acad Sci.* 2011; 108: 11878-83.
160. Kregel S, Kiriluk KJ, Rosen AM, Cai Y, Reyes EE, Otto KB, et al. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. *PLoS One.* 2013; 8: e53701.
161. Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, et al. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. *Oncogene.* 2012; 31: 4759-67.
162. Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, et al. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. *PLoS One.* 2011; 6: e27970.
163. Lu J, der Steen TV, Tindall DJ. Are androgen receptor variants a substitute for the full-length receptor? *Nat Rev Urol.* 2015; 12: 137-44.
164. Lu C, Luo J. Decoding the androgen receptor splice variants. *Transl Androl Urol.* 2013; 2: 178-186.
165. Kong D, Sethi S, Li Y, Chen W, Sakr WA, Heath E, et al. Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes: AR variants are linked with PCa progression. *Prostate.* 2015; 75: 161-74.
166. Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. *Proc Natl Acad Sci.* 2013; 110: 972-7.
167. Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. *Proc Natl Acad Sci.* 2011; 108: 1397-402.
168. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. *Cancer Res.* 2011; 71: 3196-201.
169. Mayer MJ, Klotz LH, Venkateswaran V. Metformin and prostate cancer stem cells: a novel therapeutic target. *Prostate Cancer Prostatic Dis.* 2015; 18: 303-9.
170. Vallianou NG, Evangelopoulos A, Kazazis C. Metformin and cancer. *Rev Diabet Stud.* 2013; 10: 228-35.
171. Bilen MA, Lin SH, Tang DG, Parikh K, Lee MH, Yeung SC, et al. Maintenance therapy containing metformin and/or zylflamend for advanced prostate cancer: a case series. *Case Rep Oncol Med.* 2015; 2015: 471861.
172. Li Y, Wicha MS, Schwartz SJ, Sun D. Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. *J Nutr Biochem.* 2011; 22: 799-806.
173. Scarpa ES, Ninfali P. Phytochemicals as innovative therapeutic tools against cancer stem cells. *Int J Mol Sci.* 2015; 16: 15727-42.
174. Teiten MH, Gaigneaux A, Chateauvieux S, Billing AM, Planchon S, Fack F, et al. Identification of differentially expressed proteins in curcumin-treated prostate cancer cell lines. *OMICS J Integr Biol.* 2012; 16: 289-300.
175. Botchkina GI, Zuniga ES, Rowehl RH, Park R, Bhalla R, Bialkowska AB, et al. Prostate cancer stem cell-targeted efficacy of a new-generation taxoid, SBT-1214 and novel polyenolic zinc-binding curcuminoid, CMC2.24. *PLoS One.* 2013; 8: e69884.

176. Zhang D, Tang DG, Rycaj K. Cancer stem cells: regulation programs, immunological properties and immunotherapy. *Semin Cancer Biol.* 2018; 52: 94-106.
177. Jachetti E, Mazzoleni S, Grioni M, Ricupito A, Brambillasca C, Generoso L, et al. Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses. *Oncoimmunology.* 2013; 2: e24520.
178. McNeel DG, Becker JT, Eickhoff JC, Johnson LE, Bradley E, Pohlkamp I, et al. Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. *Clin Cancer Res.* 2014; 20: 3692-704.
179. Codd AS, Kanaseki T, Torigo T, Tabi Z. Cancer stem cells as targets for immunotherapy. *Immunology.* 2018; 153: 304-14.
180. Ugolkov AV, Eisengart LJ, Luan C, Yang XJ. Expression analysis of putative stem cell markers in human benign and malignant prostate: potential stem cell markers in human prostate. *Prostate.* 2011; 71: 18-25.
181. Fan X, Liu S, Su F, Pan Q, Lin T. Effective enrichment of prostate cancer stem cells from spheres in a suspension culture system. *Urol Oncol Semin Orig Investig.* 2012; 30: 314-8.
182. Oktem G, Bilir A, Uslu R, Inan SV, Demiray SB, Atmaca H, et al. Expression profiling of stem cell signaling alters with spheroid formation in CD133high/CD44high prostate cancer stem cells. *Oncol Lett.* 2014; 7: 2103-9.
183. Kerr BA, Miocinovic R, Smith AK, West XZ, Watts KE, Alzayed AW, et al. CD117+ cells in the circulation are predictive of advanced prostate cancer. *Oncotarget.* 2015; 6: 1889-97.
184. Wiesner C, Nabha SM, Bonfil RD, Santos EBD, Yamamoto H, Meng H, et al. C-Kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. *Neoplasia.* 2008; 10: 996-1003.
185. Ricci E, Mattei E, Dumontet C, Eaton CL, Hamdy F, van der Pluijm G, et al. Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression: cancer stem cell markers and metastasis progression. *Prostate.* 2013; 73: 1738-46.
186. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. *Cancer Res.* 2005; 65: 10946-51.
187. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. *FASEB J.* 2004; 18: 1240-2.
188. Dubrovskaya A, Elliott J, Salamone RJ, Telegeev GD, Stakhovskiy AE, Schepotin IB, et al. CXCR4 expression in prostate cancer progenitor cells. *PLoS One.* 2012; 7: e31226.
189. Domanska UM, Timmer-Bosscha H, Nagengast WB, Oude Munnink TH, Kruizinga RC, Ananias HJK, et al. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. *Neoplasia.* 2012; 14: 709-18.
190. Jiao J, Hindoyan A, Wang S, Tran LM, Goldstein AS, Lawson D, et al. Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells. *PLoS One.* 2012; 7: e42564.
191. An Y, Ongkeko WM. ABCG2: the key to chemoresistance in cancer stem cells? *Expert Opin Drug Metab Toxicol.* 2009; 5: 1529-42.
192. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzmán-Ramírez N, et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. *Cancer Res.* 2010; 70: 5163-73.
193. Cojoc M, Mäbert K, Muders MH, Dubrovskaya A. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. *Semin Cancer Biol.* 2015; 31: 16-27.
194. Hoogland AM, Verhoef EI, Roobol MJ, Schröder FH, Wildhagen MF, van der Kwast TH, et al. Validation of stem cell markers in clinical prostate cancer:  $\alpha 6$ -Integrin is predictive for non-aggressive disease: stem cell markers in prostate cancer. *Prostate.* 2014; 74: 488-96.
195. Li K, Liu C, Zhou B, Bi L, Huang H, Lin T, et al. Role of EZH2 in the growth of prostate cancer stem cells isolated from LNCaP cells. *Int J Mol Sci.* 2013; 14: 11981-93.
196. Matsika A, Srinivasan B, Day C, Mader SA, Margaret Kiernan D, Broomfield A, et al. Cancer stem cell markers in prostate cancer: an immunohistochemical study of ALDH1, SOX2 and EZH2. *Pathology (Phila).* 2015; 47: 622-8.
197. Trerotola M, Ganguly KK, Fazli L, Fedele C, Lu H, Dutta A, et al. Trop-2 is upregulated in invasive prostate cancer and displaces FAK from focal contacts. *Oncotarget.* 2015; 6: 14318-28.
198. Garraway IP, Sun W, Tran CP, Perner S, Zhang B, Goldstein AS, et al. Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo: human prostate sphere-forming cells. *Prostate.* 2010; 70: 491-501.
199. Germann M, Wetterwald A, Guzmán-Ramírez N, van der Pluijm G, Culig Z, Cecchini MG, et al. Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. *Stem Cells.* 2012; 30: 1076-86.

**Cite this article as:** Banerjee P, Kapse P, Siddique S, Kundu M, Choudhari J, Mohanty V, et al. Therapeutic implications of cancer stem cells in prostate cancer. *Cancer Biol Med.* 2023; x: xx-xx. doi: 10.20892/j.issn.2095-3941.2022.0714